Market Overview:
The global iron chelation drug market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of iron overload disorders, rising awareness about these disorders, and the launch of novel drugs in this market. The global iron chelation drug market is segmented on the basis of type, application, and region. On the basis of type, it is divided into deferoxamine, deferiprone, and deferasirox. On the basis of application, it is classified into transfusional iron overload and nontransfusional hemosiderosis caused by thalassemia major (NTDT). By region, it is analyzed across North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U.K.), Asia Pacific (China Japan India Australia South Korea) Middle East & Africa(South Africa Saudi Arabia UAE).
Product Definition:
Iron Chelators are drugs that bind to iron and remove it from the body. They are used to treat conditions such as anemia, hemochromatosis, and thalassemia.
Deferoxamine:
Deferoxamine is a medication used to treat heavy metal poisoning. It works by removing the toxic substances from the body. The most common type of heavy metal poisoning is caused by lead, mercury, and copper in the human body. Lead and copper are often found in old batteries while mercury can be found in some types of medical equipment such as thermometers or blood pressure cuffs.
Deferiprone:
Deferiprone is a drug that works by removing excess iron from the body. It is used in the treatment of hemochromatosis, a disease where too much iron is taken up by the body and causes problems such as pain, arthritis, heart disease and diabetes. Deferiprone reduces absorption rate of dietary iron which helps to reduce blood drawn amount of blood for food and fluids hence reducing risk associated with Iron overload condition.
Application Insights:
The global market is segmented by application into transfusional iron overload, non-transfusional iron overload and NTDT caused iron overload. The transfusional iron overload segment dominated the overall market in terms of revenue share in 2017. This can be attributed to the rising prevalence of blood disorders coupled with a growing number of R&D initiatives for the development of novel drugs for treating these disorders.
Non-transfusal Iron Overload (NTDO) caused by increased consumption has emerged as another lucrative application area owing to increasing awareness among consumers regarding their health and wellness along with an increase in expenditure on healthcare services & products that include dietary supplements & medicines. Increasing consumer spending on healthcare is expected to drive demand from NTDO cause over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of patients suffering from NTDT-related anemia and iron overload, availability of well-established healthcare facilities, and high adoption rate for novel therapeutics are some factors attributing to its largest share. In addition, increasing R&D activities by various companies is also likely to contribute toward the growth over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising healthcare expenditure in emerging economies such as India and China along with growing patient awareness levels regarding available treatment options for NTDT-related disorders. Moreover, increasing prevalence of chronic kidney disease coupled with rising medical tourism due to affordability offered by these countries will further boost revenue generation prospects during the estimated time frame.
Growth Factors:
- Increasing prevalence of iron deficiency anemia: The increasing prevalence of iron deficiency anemia is one of the key growth drivers for the global Iron Chelation Drug market. According to a study by World Health Organization (WHO), around 30% of the world’s population is affected by this condition, which is expected to rise in the coming years. This will create a high demand for Iron Chelation Drugs and boost the market growth.
- Growing awareness about health benefits associated with chelation therapy: There is growing awareness among people about health benefits associated with chelation therapy, which is propelling the demand for Iron Chelation Drugs globally. This trend is particularly prominent in developed countries where people are increasingly opting for preventive healthcare measures to stay healthy and avoid diseases.
- Rising incidence of chronic diseases: The rising incidence of chronic diseases such as cancer, heart disease, and diabetes across the globe has led to an increase in demand for effective treatment options such as chelation therapy drugs like Iron Chelators drugs . This will spur market growth over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Iron Chelation Drug Market Research Report
By Type
Deferoxamine, Deferiprone, Deferasirox
By Application
Transfusional Iron Overload, NTDT Caused Iron Overload
By Companies
Apotex Inc. (Canada), Cipla (India), Novartis (Switzerland), Sun Pharma (India), Natco Pharma (India)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Iron Chelation Drug Market Report Segments:
The global Iron Chelation Drug market is segmented on the basis of:
Types
Deferoxamine, Deferiprone, Deferasirox
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Transfusional Iron Overload, NTDT Caused Iron Overload
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Apotex Inc. (Canada)
- Cipla (India)
- Novartis (Switzerland)
- Sun Pharma (India)
- Natco Pharma (India)
Highlights of The Iron Chelation Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Deferoxamine
- Deferiprone
- Deferasirox
- By Application:
- Transfusional Iron Overload
- NTDT Caused Iron Overload
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Iron Chelation Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Iron chelation drug is a medication that helps to remove iron from the body. Iron chelation drugs are often used to treat conditions such as anemia, heart disease, and stroke.
Some of the major players in the iron chelation drug market are Apotex Inc. (Canada), Cipla (India), Novartis (Switzerland), Sun Pharma (India), Natco Pharma (India).
The iron chelation drug market is expected to grow at a compound annual growth rate of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Iron Chelation Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Iron Chelation Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Iron Chelation Drug Market - Supply Chain
4.5. Global Iron Chelation Drug Market Forecast
4.5.1. Iron Chelation Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Iron Chelation Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Iron Chelation Drug Market Absolute $ Opportunity
5. Global Iron Chelation Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Iron Chelation Drug Market Size and Volume Forecast by Type
5.3.1. Deferoxamine
5.3.2. Deferiprone
5.3.3. Deferasirox
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Iron Chelation Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Iron Chelation Drug Market Size and Volume Forecast by Application
6.3.1. Transfusional Iron Overload
6.3.2. NTDT Caused Iron Overload
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Iron Chelation Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Iron Chelation Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Iron Chelation Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Iron Chelation Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Iron Chelation Drug Demand Share Forecast, 2019-2026
9. North America Iron Chelation Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Iron Chelation Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Iron Chelation Drug Market Size and Volume Forecast by Application
9.4.1. Transfusional Iron Overload
9.4.2. NTDT Caused Iron Overload
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Iron Chelation Drug Market Size and Volume Forecast by Type
9.7.1. Deferoxamine
9.7.2. Deferiprone
9.7.3. Deferasirox
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Iron Chelation Drug Demand Share Forecast, 2019-2026
10. Latin America Iron Chelation Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Iron Chelation Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Iron Chelation Drug Market Size and Volume Forecast by Application
10.4.1. Transfusional Iron Overload
10.4.2. NTDT Caused Iron Overload
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Iron Chelation Drug Market Size and Volume Forecast by Type
10.7.1. Deferoxamine
10.7.2. Deferiprone
10.7.3. Deferasirox
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Iron Chelation Drug Demand Share Forecast, 2019-2026
11. Europe Iron Chelation Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Iron Chelation Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Iron Chelation Drug Market Size and Volume Forecast by Application
11.4.1. Transfusional Iron Overload
11.4.2. NTDT Caused Iron Overload
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Iron Chelation Drug Market Size and Volume Forecast by Type
11.7.1. Deferoxamine
11.7.2. Deferiprone
11.7.3. Deferasirox
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
1.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Iron Chelation Drug Demand Share, 2019-2026
12. Asia Pacific Iron Chelation Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Iron Chelation Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Iron Chelation Drug Market Size and Volume Forecast by Application
12.4.1. Transfusional Iron Overload
12.4.2. NTDT Caused Iron Overload
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Iron Chelation Drug Market Size and Volume Forecast by Type
12.7.1. Deferoxamine
12.7.2. Deferiprone
12.7.3. Deferasirox
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Iron Chelation Drug Demand Share, 2019-2026
13. Middle East & Africa Iron Chelation Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Iron Chelation Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Iron Chelation Drug Market Size and Volume Forecast by Application
13.4.1. Transfusional Iron Overload
13.4.2. NTDT Caused Iron Overload
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Iron Chelation Drug Market Size and Volume Forecast by Type
13.7.1. Deferoxamine
13.7.2. Deferiprone
13.7.3. Deferasirox
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Iron Chelation Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Iron Chelation Drug Market: Market Share Analysis
14.2. Iron Chelation Drug Distributors and Customers
14.3. Iron Chelation Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Apotex Inc. (Canada)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Cipla (India)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis (Switzerland)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sun Pharma (India)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Natco Pharma (India)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
